Accountable Care OrganizationsAmbulatory Procedure/Imaging CenterAmbulatory/Office-based CareAncillary ServicesAssisted Living FacilitiesBehavioral Health CareCommunity Health CareEmergency DepartmentEmergency Medical ServicesHome CareHospicesHospital InpatientHospital OutpatientHospital â OtherIntensive Care UnitsLong-term Care Facilities - OtherManaged Care PlansNational Public Health ProgramsOtherPatient-centered Medical HomesRegional, County, or City Public Health ProgramsRehabilitation CentersResidential Care FacilitiesRural Health CareSkilled Nursing Facilities/Nursing HomesState/Provincial Public Health ProgramsSubstance Use Treatment Programs/CentersTransitionUnspecified
Lung cancer: proportion of patients with small cell lung cancer (SCLC) not undergoing treatment with curative intent who receive palliative chemotherapy.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospices, Hospital Inpatient, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with small cell lung cancer (SCLC) who receive chemotherapy ± radiotherapy.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with stage IIIB or IV non small cell lung cancer (NSCLC), with performance status 0 to 2 not undergoing surgery that are epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive who receive biological therapy.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) not undergoing surgery who receive systemic anti-cancer therapy.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with limited stage (stage I to IIIB) small cell lung cancer (SCLC), performance status 0 or 1, who receive chemoradiotherapy (radiotherapy greater than or equal to 40Gy and concurrent or sequential platinum-based chemotherapy).
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with stage IIIA non small cell lung cancer (NSCLC), with performance status 0-1, not undergoing surgery who receive chemoradiotherapy (radiotherapy greater than or equal to 54Gy and concurrent or sequential chemotherapy).
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with lung cancer not undergoing surgery who receive radiotherapy (greater than or equal to 54Gy) ± chemotherapy, or stereotactic ablative radiotherapy (SABR).
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) undergoing resection by lobectomy or pneumonectomy who have at least 1 node from at least 3 N2 stations sampled at time of resection or at previous mediastinoscopy.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Hospital Inpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with stage I to II (T1aN0 to T2bN1, or T3N0) non small cell lung cancer (NSCLC) who undergo surgical resection.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Hospital Inpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) who undergo surgical resection.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Hospital Inpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who undergo PET CT prior to start of treatment.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Inpatient, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with a pathological diagnosis of stage IIIB or IV non small cell lung cancer (NSCLC) who have molecular profiling undertaken.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with a pathological diagnosis of non small cell lung cancer (NSCLC) who have a tumour subtype identified.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with lung cancer who have a pathological diagnosis (including following surgical resection).
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lung cancer: proportion of patients with lung cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Inpatient, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lymphoma: proportion of patients with lymphoma undergoing rituximab based treatment who have hepatitis B, hepatitis C and HIV status checked prior to treatment.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lymphoma: proportion of patients with primary cutaneous lymphoma who are discussed at a specialist multidisciplinary team (MDT) meeting.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Inpatient, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lymphoma: proportion of patients with early stage (stage 1a or 2a) classical Hodgkin lymphoma (CHL) who receive combined modality treatment (chemotherapy and radiotherapy).
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lymphoma: proportion of patients with nodal, non-bulky stage 1a diffuse large B-cell lymphoma (DLBCL) who receive local radiotherapy, in combination with chemotherapy.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
Lymphoma: proportion of patients with grade 3b follicular lymphoma who receive treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) chemotherapy.
- Published By NHS Scotland, Scottish Cancer Taskforce
- Measurement Settings Ambulatory/Office-based Care, Ambulatory Procedure/Imaging Center, Hospital Outpatient
- Professionals Involved In the Delivery of Service
